Servier Canada Inc is the Canadian affiliate of The Servier Research Group, a leading French research based organisation, specializing in ethical pharmaceuticals.
In the short span of fifty five years, the Servier Research Group has developed in stature from a family-owned, provincial pharmacy employing nine people to a multi-national operation with over 20,000 employees, including 3,000 in R&D, yet the Company is still privately-owned and is still passionately and permanently committed to remaining independent.
In Canada, Servier’s activities commenced in February 1978 in a modest location in Pointe-Claire, Quebec with a total staff of three employees. Within a month of its opening, a Sales supervisor and seven sales representatives were recruited and working in the region of Quebec. From 1985-1991, Servier Canada continued to gradually expand its presence across Canada, with growth in both its size of sales force and the number of head office employees. By 1994, the Company had moved to new premises in Laval, Quebec, where its current facility resides.
Servier Canada is committed to the investment in research and development and was proud to join Canada’s Research Based Pharmaceutical Companies (Rx&D) in 1995.
Contact
Drs Neil Cashman and Larry Altstiel of ProMIS Neurosciences weigh in on recent progress towards an effective therapy for Alzheimer’s disease, potentially representing a break from three decades of scientific…
Some of the top stories coming out of Canadian healthcare and life sciences, including a new GSK flu vaccine deal, Amylyx Pharmaceuticals’ first approval for an ALS drug, and the…
In April, the Canadian Ministry of Health announced the government would not be proceeding with certain proposed amendments to the Patented Medicines Regulations which govern the Patented Medicine Prices Review…
In conversation in the October edition of DIA’s Global Forum magazine, Canadian Agency for Drugs and Technologies in Health (CADTH) CEO Suzanne McGurn highlights how the work of HTA bodies…
Writing in the September edition of DIA’s Global Forum magazine, Dr Judith Glennie examines the specific steps that have been taken in the journey towards a National Pharmacare program in…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada’s consultation with Canadians on what a national strategy for high-cost rare disease…
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its current legal status, provincial variations in patient registrations, financial performance, the impact…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the concept of ‘national pharmacare’ for…
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt end to Canada’s participation in CanSino Biologics’ clinical trials the country’s first medical cannabis…
Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory body to reconsider their implementation. Companies cite the push for cost-effectiveness as a reason for…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading…
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the forefront of the next wave of global biopharmaceutical R&D. BlueRock Therapeutics, a promising…
See our Cookie Privacy Policy Here
